Researchers discovered that injecting drugs in between two layers of the eyeball allows for a more targeted delivery.
Credit: iStock.com/CreVis2
To get drugs to reach the choroid and retina, ophthalmologists have relied on imperfect methods with drawbacks. Suprachoroidal delivery could be the fix.
Revolutionizing Eye Care: The Rise of Suprachoroidal Drug Delivery
The field of ophthalmology is on the cusp of a significant transformation. Researchers are pioneering innovative drug delivery methods that promise to revolutionize how we treat a wide array of eye conditions. At the forefront of this wave is suprachoroidal drug delivery, a technique offering unprecedented precision and efficacy.
The Challenge of Traditional Eye Treatments
For many years, ophthalmologists have grappled with the limitations of existing drug delivery methods. Eye drops, while convenient for treating conditions affecting the front of the eye, struggle to reach the choroid and retina at the back of the eye. Intravitreal injections, which deliver drugs directly into the eye’s vitreous humor, can be effective but often come with the risk of off-target effects. Invasive retinal surgery, though sometimes necessary, carries its own set of risks. And systemic delivery, where drugs are administered throughout the body, often leads to unwanted side effects.
What is Suprachoroidal Drug Delivery?
Suprachoroidal drug delivery (SCD) offers a compelling alternative. It involves injecting medication into the suprachoroidal space, the area between the sclera (the white of the eye) and the choroid (the layer of blood vessels). This space, which is typically nonexistent, opens up when a fluid is precisely injected, allowing targeted drug delivery to the back of the eye. This precision minimizes off-target effects and enhances the therapeutic impact.
As Dr. Mark Prausnitz, a chemical engineer at the Georgia Institute of Technology, puts it: “It opens up a whole new door in ophthalmology.”
Real-World Success: Xipere and Beyond
One of the first significant breakthroughs in this field came with the development of Xipere, a combination product approved by the FDA in 2021. This innovative treatment delivers a steroid drug directly into the suprachoroidal space to treat macular edema associated with uveitis (a type of eye inflammation). Clearside Biomedical, the company behind Xipere, is actively developing other drugs for this delivery method.
FDA Approval of Xipere marked a pivotal moment, demonstrating the clinical viability and safety of SCD.
Clearside Biomedical’s Chief Medical Officer, Victor Chong, emphasizes that the company is using this device “as a platform company to deliver different drugs.”
The Potential of Suprachoroidal Delivery for Gene Therapy
One of the most exciting applications of suprachoroidal drug delivery lies in the realm of gene therapy. This approach delivers therapeutic genes directly to the back of the eye, potentially treating a range of inherited retinal diseases. Unlike traditional subretinal injections, which require invasive surgery, SCD offers a less traumatic delivery method. It can also offer a more targeted approach compared to intravitreal delivery, which can cause inflammation.
Companies are actively researching SCD for gene therapies targeting diseases such as diabetic retinopathy and wet age-related macular degeneration (wet AMD). Clinical trials are underway, holding the promise of improved outcomes and reduced side effects.
Innovative Glaucoma Treatment: A New Horizon
Beyond gene therapy, the potential of SCD extends to treating glaucoma. Researchers are exploring the use of hydrogels injected into the suprachoroidal space to reduce intraocular pressure, the primary cause of glaucoma. This innovative approach could provide a long-lasting treatment option, offering a new way to manage this debilitating condition.
The beauty of SCD lies in its simplicity and precision, allowing doctors to target the back of the eye specifically without causing potentially harmful side effects. The potential to administer drugs directly where they are most needed will change the way many eye diseases are treated in the future.
The Road Ahead: Challenges and Opportunities
While the future of suprachoroidal drug delivery is bright, challenges remain. Developing effective formulations that work well within the suprachoroidal space is crucial. However, the ongoing research and development efforts, combined with encouraging clinical trial results, point to a promising future for this innovative technique.
The focus is on developing combination products, with devices and drugs designed to work seamlessly together, which will allow for the greatest precision and efficacy.
FAQ: Frequently Asked Questions about Suprachoroidal Drug Delivery
What is the suprachoroidal space?
The suprachoroidal space is a potential space located between the sclera (the white of the eye) and the choroid (the layer of blood vessels). It is typically non-existent but can be opened through targeted injections.
What are the benefits of suprachoroidal drug delivery?
It allows for targeted drug delivery to the back of the eye, minimizing off-target effects, and offering enhanced therapeutic impact compared to traditional methods.
What eye conditions can be treated with suprachoroidal drug delivery?
It is being used to treat conditions like macular edema, uveitis, diabetic retinopathy, wet AMD, and glaucoma, with ongoing research exploring its potential for other diseases.
Is suprachoroidal drug delivery safe?
Early clinical trials and post-marketing data suggest that SCD is safe.
Did you know? Suprachoroidal drug delivery has already been used in more than 15,000 injections!
Seize the Future: Take Action Now
The development of suprachoroidal drug delivery is an exciting advancement.
To stay informed about the latest developments in eye care, subscribe to our newsletter and explore more articles on cutting-edge medical technologies. Share your thoughts and opinions in the comments below.
Keep reading